Evidence map›Paper›PMID 37164012›Full record

ArticleCell2023

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection.

Christina M Arieta, Yushu Joy Xie, Daniel A Rothenberg, Huitian Diao, Dewi Harjanto, Shirisha Meda, Krisann Marquart, Byron Koenitzer, Tracey E Sciuto, Alexander Lobo and 17 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The ageing immune system and its battle with viruses.The Journal of general virology · 2026
    Review
  5. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  6. Distinct CD8iScience · 2026
    Article
  7. Article
  8. A new mRNA antigen vaccine induces potent B and T cell responses andbioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 2 institutions in 2 countries.

Christina M ArietaBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA. Electronic address: christina.arieta@biontech.us.
Yushu Joy XieBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Daniel A RothenbergBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Huitian DiaoBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Dewi HarjantoBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Shirisha MedaBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Krisann MarquartBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Byron KoenitzerBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Tracey E SciutoBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Alexander LoboBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Adam ZuianiBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Stefanie A KrummBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Carla Iris Cadima CoutoBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Stephanie HeinBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
André P HeinenBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Thomas ZiegenhalsBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Yunpeng Liu-LupoBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Annette B VogelBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
John R SroujiBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Stephanie FesserBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Kaushik ThankiBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Kerstin WalzerBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.
Theresa A AddonaBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Özlem TüreciBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany; HI-TRON - Helmholtz Institute for Translational Oncology Mainz by DKFZ, Obere Zahlbacherstr. 63, 55131 Mainz, Germany.
Uğur ŞahinBioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany; TRON gGmbH - Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Freiligrathstraße 12, 55131 Mainz, Germany.
Richard B GaynorBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.
Asaf PoranBioNTech US, 40 Erie Street, Cambridge, MA 02139, USA. Electronic address: asaf.poran@biontech.us.
BioNTech (United States) · USBioNTech (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell responses play an important role in protection against beta-coronavirus infections, including SARS-CoV-2, where they associate with decreased COVID-19 disease severity and duration. To enhance T cell immunity across epitopes infrequently altered in SARS-CoV-2 variants, we designed BNT162b4, an mRNA vaccine component that is intended to be combined with BNT162b2, the spike-protein-encoding vaccine. BNT162b4 encodes variant-conserved, immunogenic segments of the SARS-CoV-2 nucleocapsid, membrane, and ORF1ab proteins, targeting diverse HLA alleles. BNT162b4 elicits polyfunctional CD4

Indexed as

BNT162 VaccineCOVID-19AnimalsAntibodies, NeutralizingAntibodies, ViralCricetinaeEpitopesHumansSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineEpitopesCOVID-19HLA ligandomicsimmune protectionmRNA T cell vaccineSARS-CoV-2T cell responsesvaccine designviral variants

Identifiers

PMID37164012
PMCPMC10099181
OpenAlexW4365447189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.